This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Ulcerative proctitis궤양성 (만성) 직장염

Contents and key points
ItemDetails
A. Classification codesICD-10: K51.2 (Ulcerative proctitis) | Special Copayment Reduction: V131 (severe intractable disease, 5 years)
B. Synonymsulcerative proctitis, proctitis ulcerosa, rectal ulcerative colitis
C. Adult onsetAdult onset high — proctitis is the most common initial form of UC, accounting for 30~40% of all UC. Age at diagnosis is later than for pancolitis, with onset mainly in the 30s–50s.
1. HistorySince Wilks's description in 1859, rectal involvement recognized as the most common form → 1980s introduction of rectal 5-ASA preparations established the concept of topical treatment
2. CausesSame multifactorial cause as UC; local rectal microbial and immune environment contributes to rectum-limited expression
3. GeneticsLoci shared with UC such as HLA-DR2, IL-10, and ECM1; research on proctitis-specific genetic predisposition ongoing
4. General epidemiology30~40% of UC patients begin with proctitis; about 30~50% progress proximally (proximal extension) within 10 years; low surgery rate
5. PathophysiologyRectal mucosal barrier damage, local Th2/Th9 immune activation, neutrophil infiltration, repeated irritation linked to rectal defecation physiology
6. SymptomsRectal bleeding, mucoid stool, urgency, tenesmus after defecation, constipation (paradoxical, with rectal spasm)
7. SignsLower abdominal tenderness, abnormal digital rectal examination, erythema and ulcers on proctoscopy, elevated fecal calprotectin, mildly elevated or normal CRP
8. ScreeningFecal calprotectin, proctoscopy/sigmoidoscopy; differentiation of causes of rectal bleeding is essential
9. DiagnosisColonoscopy (or sigmoidoscopy) + biopsy; confirm continuous mucosal inflammation limited to the rectum; differentiate sexually transmitted proctitis
10. TreatmentFirst line: rectal 5-ASA suppository ± oral 5-ASA; refractory: steroid enema/suppository; severe refractory: biologics
11. PrognosisBest prognosis among UC; low surgery rate; however, prognosis worsens with proximal extension; quality-of-life impairment is large relative to symptom severity
12. PreventionRectal 5-ASA maintenance treatment; surveillance endoscopy for proximal extension; prevention of infectious proctitis (prevention of sexually transmitted diseases)
13. ReferencesKamm et al. Gut 2007; Regueiro et al. Am J Gastroenterol 2016 and 8 others

1. History

Ulcerative proctitis is a phenotype of ulcerative colitis (UC) in which inflammation is confined to the rectum. Since Wilks in 1859, when the clinical description of UC began, clinicians have recognized involvement of the lower colon, including the rectum, as the most common initial form of UC. From the late 19th to the early 20th century, observation of the rectal mucosa became possible with the rigid proctoscope, and erythema, edema, loss of vascular pattern, spontaneous bleeding, and ulcers of the rectal mucosa were described as characteristic findings of UC.

With the introduction of the flexible sigmoidoscope in the 1950s–60s, observation up to the rectosigmoid junction became easy, and the clinical concept distinguishing proctitis from proctosigmoiditis became established. It was clinically emphasized that functional symptoms (urgency, tenesmus, constipation) are prominent in proctitis, and attention was drawn to the fact that the impact of these symptoms on quality of life is excessive relative to the extent of the lesions.

In the history of treatment, the development of rectal mesalazine (5-ASA) preparations was the most important turning point. With the introduction of 5-ASA suppositories and enemas in the 1980s, treatment confined to the rectum became possible, establishing a strategy that minimizes systemic adverse effects while enhancing local therapeutic effect. A study by Kamm et al. (2007) confirmed that rectal 5-ASA suppository combined with oral 5-ASA further increases the remission rate. Rectal steroid preparations (hydrocortisone foam, budesonide enema) were subsequently established as second-line options. After the 2010s, biologics (infliximab, vedolizumab, etc.) began to be used even in proctitis refractory to 5-ASA and steroids.


2. Causes

The cause of ulcerative proctitis is fundamentally the same as that of other UC phenotypes such as pancolitis, and is explained by a complex interaction of genetic predisposition, gut microbial abnormality, immune dysregulation, and environmental factors. However, a separate mechanism is being explored for why inflammation is confined to the rectum.

Local rectal environment

Unlike other parts of the colon, the rectum is a tightly contracted defecation reservoir with continuous fecal exposure and mechanical irritation. The immune environment of the rectal mucosa (especially the local IgA secretion pattern and distribution of mucosa-associated lymphoid tissue) differs from other colonic segments, and these local immune characteristics may contribute to inflammation being induced or sustained only in the rectum. In addition, the rectum is directly influenced by the flora of the anal canal and is a site requiring differentiation from sexually transmitted infections (gonococcal, chlamydial, herpes simplex, etc.).

Microbial factors

Gut microbial dysbiosis in UC patients is also observed in the rectum, and an increase in specific bacteria such as Fusobacterium nucleatum and Bacteroides fragilis and a decrease in beneficial bacteria such as Faecalibacterium prausnitzii are reported. The interaction between rectal microbiota and mucosal immunity contributes to persistent activation of proctitis.

Environmental factors

As with pancolitis, smoking has a paradoxical protective effect in proctitis. Antibiotic use, NSAIDs, and a high-fat diet are being studied as risk factors. There is evidence that psychological stress worsens rectal hypersensitivity through the gut-brain axis and triggers relapse.


3. Genetics

The genetic basis of ulcerative proctitis is largely shared with other UC phenotypes such as pancolitis. In GWAS studies, many of the roughly 200 susceptibility loci common to UC also show association in proctitis.

HLA association: HLA-DR2 (DRB1*15:02) is the strongest genetic risk factor across UC, including proctitis. In particular, HLA-DRB1*01503 has been reported to be strongly associated with rectum-limited UC. A hypothesis has been proposed that specific haplotypes of the HLA region may determine the tendency toward rectum-limited expression or proximal extension, but large confirmatory studies are still lacking.

IL-10 receptor genes: Function-preserving polymorphisms of the IL-10RA and IL-10RB genes are involved in UC overall, and reduced IL-10 signaling in the rectal mucosa weakens local Treg function and contributes to maintenance of chronic rectal inflammation.

ECM1 and LAMB1: Polymorphisms of genes related to the epithelial extracellular matrix and barrier function (ECM1, LAMB1) are associated with UC susceptibility and may affect abnormalities of the basement membrane structure of the rectal mucosa. There are studies analyzing differences in gene expression profiles between patients whose proctitis progresses proximally and those whose does not, but a clear predictive biomarker has not yet been established.

Drug response-related genes: Polymorphisms of the TPMT (thiopurine methyltransferase) and NUDT15 genes determine the risk of azathioprine/6-MP toxicity (bone marrow suppression), and genetic testing before treatment is recommended. In East Asians, the NUDT15 variant (R139C) is more common than in Westerners, so azathioprine dose reduction is often needed.


4. General epidemiology

Ulcerative proctitis is the most common initial phenotype of UC, accounting for about 30~40% of all UC. Age at diagnosis is relatively higher than for pancolitis (median 35~45 years), and it occurs frequently in adults. The incidence is relatively similar between men and women.

Disease progression (proximal extension): About 30~50% of UC patients who begin with proctitis are reported to progress to more extensive colonic involvement (sigmoiditis or beyond) within 10 years of diagnosis. Risk factors for proximal extension include young age at diagnosis, high disease activity, extensive biopsy abnormalities, and accompanying PSC. Proximal extension requires escalation of treatment intensity, and the prognosis is also worse than with proctitis alone.

Epidemiology in Korea: The proportion of proctitis among UC patients in Korea is reported to be similar to or slightly lower than in the West. In pediatric and adolescent UC, the proportion of proctitis is lower than in adults, and the proportion of pancolitis is relatively higher. Patients with proctitis have markedly lower hospitalization and surgery rates than those with pancolitis or left-sided colitis.

Colorectal cancer risk: The colorectal cancer risk in proctitis is markedly lower than in pancolitis, and the increase in CRC risk is minimal in rectum-limited UC. However, if it progresses to pancolitis, CRC risk rises, so regular endoscopic surveillance is needed.


5. Pathophysiology

The pathophysiology of ulcerative proctitis shares the same pathophysiology as pancolitis, but reflects the anatomical and immunological particularities of the rectum.

Rectal mucosal barrier abnormality

Reduced expression of tight junction proteins (claudin, occludin) in the rectal mucosa and decreased goblet cell mucin secretion increase mucosal permeability and promote invasion of fecal bacterial antigens into the lamina propria. Because the rectum is an environment continuously exposed to bacterial antigens owing to its fecal storage function, barrier dysfunction can cause rectum-selective inflammation.

Innate and adaptive immune responses

Dendritic cells and macrophages in the rectal lamina propria recognize microbial antigens exposed through increased intestinal permeability via TLRs and secrete IL-1β, IL-6, and TNF-α. In adaptive immunity, Th2 (IL-13) and Th9 (IL-9)-skewed responses are activated in the rectal mucosa, inducing epithelial damage and neutrophil infiltration. The abundant mucosa-associated lymphoid tissue (MALT) of the rectum acts as a base for amplifying immune responses.

Neuro-immune interaction

The rectum is richly connected to the pelvic plexus and is under the regulation of the sympathetic and parasympathetic nerves and the enteric nervous system (ENS). In rectal inflammation, changes in the enteric nervous system cause rectal hypersensitivity, so that functional symptoms such as urgency and tenesmus appear excessive relative to the degree of mucosal inflammation. This explains why severe urgency unrelated to rectal diameter is a characteristic symptom of proctitis.


6. Symptoms

The symptoms of ulcerative proctitis reflect inflammation confined to the rectum; systemic symptoms are mild compared with pancolitis, but rectum-related functional symptoms are prominent.

Main symptoms

Rectal bleeding is the most characteristic symptom, appearing as bright red blood coating the stool surface or staining toilet paper after defecation. Unlike pancolitis, small amounts of bright red blood rather than massive bloody stool are characteristic. Mucoid stool and urgency are common, accompanied by lower abdominal cramping pain before defecation. Tenesmus is a highly characteristic symptom of proctitis, with a persistent urge to defecate and a feeling that the rectum is not completely emptied even after defecation. This is due to decreased rectal compliance caused by rectal mucosal inflammation and nervous system hypersensitivity.

Paradoxical constipation: Defecation disorder can occur because of rectal spasm and hypersensitivity, and in fact some proctitis patients complain of constipation rather than diarrhea. This is 'paradoxical constipation', in which stool is retained in the upper rectum owing to abnormal rectal motility. In this case, caution is needed because enema administration may actually worsen symptoms.

Systemic symptoms

Systemic symptoms are mild in proctitis compared with pancolitis. Fever, weight loss, and severe anemia are rare. However, mild iron deficiency anemia due to repeated bleeding may occur, and chronic fatigue reduces quality of life. Extraintestinal symptoms (arthralgia, skin symptoms, uveitis, etc.) occur less frequently than in pancolitis.

Psychological impact

The symptoms of proctitis (urgency, tenesmus, bleeding), despite relatively mild endoscopic findings, seriously affect daily life, occupational function, social activities, and sleep, and are strongly associated with reduced quality of life and the development of anxiety and depression.


7. Signs

The physical signs of ulcerative proctitis reflect inflammation confined to the rectum and are often mild.

Physical findings

Mild tenderness in the lower abdomen (especially left lower abdomen) or above the pubis may be present. Systemic signs (fever, tachycardia, hypotension) are mostly absent. On digital rectal examination, tenderness of the rectal mucosa and bloody discharge may be found, and when a rectal stricture accompanies, resistance to finger passage is felt. Perianal lesions (fistula, abscess, etc.) are characteristic of Crohn disease, so they are differentiated when proctitis is diagnosed.

Test findings

On blood tests, CRP and ESR may be mildly elevated or within the normal range, reflecting the limited extent of lesions in proctitis. Anemia appears as a mild iron deficiency pattern (Hb from the lower normal limit to mildly reduced). Fecal calprotectin is elevated in active proctitis, but often shows lower values than in pancolitis. In rectal biopsy, crypt architectural distortion, basal plasmacytosis, neutrophil infiltration, and goblet cell depletion are observed.

Endoscopic findings

Continuous mucosal inflammation confined to the rectum is characteristic, with a clear boundary at the rectosigmoid junction. Erythema, edema, loss of vascular pattern, granular mucosa, contact bleeding, and ulcers are observed in the rectal mucosa. The colon above the rectum maintains normal mucosa.


8. Screening

Screening of the general population for ulcerative proctitis is not recommended. However, in patients complaining of rectal bleeding, differentiation of the cause is essential, and differentiation from hemorrhoids, anal fissure, colorectal cancer, sexually transmitted proctitis, etc. is particularly important.

Noninvasive screening

Fecal occult blood testing is used to screen for organic causes of rectal bleeding. Fecal calprotectin is a sensitive marker of intestinal mucosal inflammation and is useful for differentiating functional bowel disease (IBS) from organic bowel disease. Calprotectin <50 μg/g makes active intestinal inflammation unlikely, and >150 μg/g prompts endoscopy.

Endoscopic evaluation

In patients complaining of rectal bleeding, mucoid stool, urgency, and tenesmus, flexible sigmoidoscopy or total colonoscopy is the primary diagnostic test. Sigmoidoscopy can examine the rectosigmoid region and is useful for early diagnosis of proctitis, but total colonoscopy is performed at the time of diagnosis or early to confirm the extent of lesions, exclude Crohn disease, and for colorectal cancer surveillance. In follow-up once UC has been established after initial diagnosis, rectal activity can be monitored with sigmoidoscopy.

Differentiation from sexually transmitted proctitis

In men who have sex with men and sexually active young and middle-aged adults complaining of rectal bleeding and mucoid stool, culture and nucleic acid amplification testing (NAAT) are needed to differentiate gonococcal (Neisseria gonorrhoeae), chlamydial (Chlamydia trachomatis), herpes simplex (HSV), syphilitic (Treponema pallidum), and amebic proctitis.


9. Diagnosis

Diagnosis of ulcerative proctitis integrates clinical symptoms, endoscopic findings, and histopathological findings, and it is essential to exclude infectious causes and Crohn disease.

Colonoscopy and biopsy

Total colonoscopy distinguishes proctitis from pancolitis and left-sided colitis by confirming continuous inflammation confined to the rectum and a normal upper colon. The terminal ileum is also examined and used for differentiation from Crohn disease. Biopsies are taken from both the rectum and normal segments (sigmoid colon, ascending colon, etc.) and the histopathology is compared. Confirmation of crypt architectural distortion, basal plasmacytosis, neutrophil infiltration, goblet cell depletion, and Paneth cell metaplasia in rectal tissue is consistent with a UC diagnosis.

Differential diagnosis

Sexually transmitted proctitis (gonorrhea, chlamydia, HSV, syphilis) is excluded by culture and nucleic acid amplification testing, taking sexual activity and route of contact into account. Crohn proctitis is differentiated by perianal lesions (fistula, anal abscess), skip lesions, upper small bowel involvement, granulomas, etc. Ischemic proctitis is considered in elderly patients with vascular disease risk factors. Radiation proctitis is differentiated from a history of pelvic radiation therapy.


10. Treatment

Treatment of ulcerative proctitis centers on topical rectal preparations, with systemic treatment added stepwise when refractory.

First-line treatment: rectal 5-ASA

Mesalazine rectal suppository (500 mg~1 g once daily) is the first-line treatment for mild-to-moderate proctitis. Mesalazine suppositories deliver the drug directly to the rectum and maintain a high local concentration without systemic adverse effects. The remission induction rate is about 60~70%, superior to oral 5-ASA alone. Combination of oral mesalazine (2.4~4.8 g/day) and rectal suppository has higher remission induction and remission maintenance rates than topical treatment alone and is currently recommended in international guidelines.

Second-line treatment: rectal steroids

When 5-ASA is ineffective, rectal steroids (hydrocortisone foam or budesonide enema) are added. Budesonide enema (2 mg/100 mL) combines high local effect with low systemic absorption, so corticosteroid-related systemic adverse effects are few with long-term use. However, long-term use of high-dose steroid enemas is avoided, and after remission induction the patient is switched to 5-ASA maintenance.

Severe refractory proctitis

When topical treatment and oral 5-ASA are ineffective, or steroid dependence or resistance develops, an immunosuppressant (azathioprine) or a biologic (infliximab, vedolizumab) is used. Cases in which proctitis progresses proximally or systemic treatment is needed are also indications for biologics. JAK inhibitors (tofacitinib, upadacitinib) are also an alternative in severe refractory disease.

Maintenance treatment

After remission is achieved, maintenance is provided with mesalazine rectal suppositories every other day or every 2~3 days, or with continued long-term oral mesalazine. Because the relapse rate is high when 5-ASA maintenance treatment is stopped, long-term administration is the rule.


11. Prognosis

Ulcerative proctitis has the best prognosis among the UC phenotypes. The surgery rate is low (<5% within 5~10 years), and colorectal cancer risk is also markedly lower than in pancolitis. However, repeated relapse of symptoms continuously reduces quality of life, and prognosis worsens with proximal extension.

Disease course

About 40~50% of proctitis patients show a relatively stable course even without appropriate treatment, but treatment must be intensified in patients with repeated relapse. The duration of remission varies greatly among individuals, and stress, infection, and NSAID use act as triggers of relapse. With proximal extension, about 20~30% of patients progress to left-sided colitis or beyond within 5 years of proctitis diagnosis and about 30~50% within 10 years.

Quality of life

The symptoms of proctitis (especially urgency and tenesmus) seriously impair social activities, sleep, and occupational function and are strongly associated with anxiety and depression. Since studies show that achieving endoscopic remission (mucosal healing) is more strongly associated with improved quality of life than clinical remission, a treat-to-target strategy aiming at mucosal healing beyond symptom remission is recommended.


12. Prevention

Primary prevention of ulcerative proctitis is not possible, but prevention of relapse and surveillance for proximal extension are important.

Prevention of relapse

After remission is achieved, maintenance administration of mesalazine rectal suppositories is the most effective for lowering the relapse rate. When a patient shows reluctance to use topical preparations, switch to oral 5-ASA, while explaining that combined topical and oral use is superior to either alone. Symptom relapse and changes in calprotectin are monitored through regular outpatient visits (at 3~6-month intervals).

Surveillance for proximal extension

In patients diagnosed with proctitis, if symptoms worsen (increased bloody stool, increased stool frequency, onset of systemic symptoms), proximal extension is suspected and total colonoscopy is performed. Follow-up endoscopy is performed within 1~2 years of diagnosis to confirm changes in the extent of lesions, and 8~10 years after diagnosis colorectal cancer surveillance endoscopy begins regardless of whether pancolitis is present.

Prevention of sexually transmitted proctitis

In high-risk groups in whom differentiation from sexually transmitted proctitis is important, safe sexual behavior (condom use, limiting the number of partners) and regular testing for sexually transmitted diseases are recommended.


13. References

  1. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66-75. DOI: 10.1053/j.gastro.2006.10.011.
  2. Regueiro M, Rodemann J, Kip KE, et al. Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflamm Bowel Dis. 2011;17(4):1008-1014. DOI: 10.1002/ibd.21451.
  3. Ford AC, Khan KJ, Achkar JP, Moayyedi P. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Proctitis: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(2):167-176. DOI: 10.1038/ajg.2011.410.
  4. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413. DOI: 10.14309/ajg.0000000000000152.
  5. Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74. DOI: 10.1038/s41572-020-0205-x.
  6. Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. J Crohns Colitis. 2017;11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008.
  7. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431-440. DOI: 10.1080/00365520802600961.
  8. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. DOI: 10.1136/gutjnl-2019-318484.
  9. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4(4):431-437. DOI: 10.1016/j.crohns.2010.02.001.
  10. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-607. DOI: 10.1136/gut.2010.224600.